SHERIDAN, WYOMING - April 4, 2026 - Dental clinicians managing deep cavity restorations and endodontic retreatment decisions now have a richer evidence base to draw from, as Septodont USA's February 2026 clinical newsletter consolidates two-year trial outcomes for BioRoot® Flow and four documented case studies applying Biodentine® in the Bio-Bulk Fill technique for indirect restorations.
Biodentine Bio-Bulk Fill: four clinical cases document deep cavity restoration
Septodont's Case Studies Collection 28 presents workflows from four clinicians who used Biodentine®'s dentine-like mechanical and biological properties to restore deep cavities using the Bio-Bulk Fill technique. The cases extend the application of the material to symptomatic cracked teeth - a notoriously difficult clinical scenario where pulp status is uncertain and cavity geometry is irregular.
Each case study in the collection includes step-by-step workflows that take the clinician from initial Biodentine® placement through to completion of the indirect restoration. This structured documentation approach gives practitioners a replicable protocol rather than isolated anecdote, making it directly applicable to chair-side decision-making. The emphasis on cracked teeth cases is clinically significant: these presentations frequently result in extraction or root canal therapy when restorative options are not well-supported by evidence, so documented conservative outcomes carry immediate relevance for treatment planning.
BioRoot Flow two-year multicenter trial results: 91% success rate
Professor Stéphane Simon presented multicenter randomized trial results for BioRoot® Flow at the Pulp Summit, reporting a 91% two-year clinical success rate for the hydraulic bioceramic sealer. The multicenter and randomized design of the trial places these results at a higher level of evidence than single-center or retrospective studies, which is relevant for practitioners and procurement officers evaluating whether to standardize on bioceramic sealer systems.
The Pulp Summit lecture also covers practical integration of BioRoot® Flow into everyday endodontic workflows. Hydraulic bioceramic sealers represent a shift from traditional epoxy-resin systems, requiring adjustments in obturation technique, working time management, and instrument sequencing. Guidance on seamless workflow adoption lowers the barrier for practices that have delayed adoption pending clearer clinical evidence - which the two-year multicenter data now provides.
Septodont CSR Report: solidarity pillar and community dental access
Septodont's latest Corporate Social Responsibility Report addresses four pillars, with Pillar 4 - Nurture Solidarity - covering its commitments to dental care access, education and knowledge sharing, and long-term partnerships with local charities. The report frames these activities as contributions to more inclusive and resilient communities rather than philanthropic add-ons, positioning them within a structured CSR framework.
For dental education institutions and public health organizations evaluating supplier partnerships, Septodont's documented solidarity commitments provide a measurable non-commercial dimension to its market positioning. Supporting access to dental care directly intersects with ongoing discussions in North American dental public health about underserved community access, giving this pillar practical context beyond corporate reporting.
Business impact
Dental practice procurement leads and clinical directors evaluating restorative material portfolios in 2026 can use the Biodentine® Bio-Bulk Fill case series to validate a conservative cavity management strategy that may reduce referral rates to endodontic specialists and preserve tooth structure in cases that might otherwise trend toward extraction. The four documented step-by-step protocols reduce the training investment needed to introduce the technique across a multi-site practice or DSO environment.
Endodontic product managers and group purchasing organizations assessing bioceramic sealer adoption now have a two-year multicenter randomized dataset supporting BioRoot® Flow at 91% success. This shifts the conversation from trial adoption to formulary standardization. Practices that deferred sealer transitions pending stronger evidence face a lower justification threshold for maintaining legacy epoxy-resin systems. For technology roadmap decisions in endodontics, the Pulp Summit evidence positions BioRoot® Flow as a viable default rather than an emerging alternative, with concrete implications for 2026 consumable sourcing budgets and clinical protocol updates.